HSD17B4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL22867380	1.00	4/20
SCHEMBL22867412	1.00	4/20
SCHEMBL22867634	1.00	4/20
SCHEMBL22867856	1.00	4/20
SCHEMBL30359792	1.00	4/20
SCHEMBL30359807	1.00	4/20
SCHEMBL22867632	0.91	4/20
SCHEMBL22867641	0.91	4/20
SCHEMBL30359777	0.91	4/20
SCHEMBL30359780	0.91	4/20
SCHEMBL22867383	0.90	4/20
SCHEMBL22867719	0.90	4/20
SCHEMBL29581516	0.90	4/20
SCHEMBL30359648	0.90	4/20
SCHEMBL22867381	0.84	4/20
SCHEMBL30359655	0.84	4/20
SCHEMBL22867650	0.83	4/20
SCHEMBL22867628	0.82	4/20
SCHEMBL30359666	0.82	4/20
SCHEMBL22867379	0.81	4/20

Clinical trials — most relevant to HSD17B4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.	PHASE4	COMPLETED
Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate	PHASE4	NOT_YET_RECRUITING
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Betaine and Peroxisome Biogenesis Disorders	PHASE3	COMPLETED
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)	PHASE3	COMPLETED
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris	PHASE1/PHASE2	UNKNOWN
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease	EARLY_PHASE1	COMPLETED
Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)	nan	RECRUITING
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency	nan	UNKNOWN
Familial Partial Lipodystrophy Study	nan	COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing	nan	COMPLETED
Gene Polymorphisms Influencing Steroid Synthesis and Action	nan	WITHDRAWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Genetic and Metabolic Disease in Children	nan	RECRUITING
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People	nan	COMPLETED
Lifestyle Intervention in Fatty Liver (NAFLD)	nan	UNKNOWN
Hepatic Lipid Metabolism-Alcohol Use Disorder	nan	RECRUITING
Omics-based Predictors of NAFLD/Potential NASH	nan	UNKNOWN
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HSD17B4 binder may also engage these)

Protein	Name	Similarity
P51660	—	1.000	P51660 →
P97852	—	1.000	P97852 →
Q9VXJ0	—	0.993	Q9VXJ0 →
Q9NKW1	—	0.988	Q9NKW1 →
Q01373	—	0.987	Q01373 →
Q02207	—	0.987	Q02207 →
HSDL2	Hydroxysteroid dehydrogenase-like protein 2	0.984	landscape →
Q5RA68	—	0.983	Q5RA68 →
Q8K009	—	0.981	Q8K009 →
Q6P5L8	—	0.981	Q6P5L8 →
Q9WVK3	—	0.980	Q9WVK3 →
Q66KC4	—	0.980	Q66KC4 →
Q9HDG2	—	0.980	Q9HDG2 →
Q12627	—	0.980	Q12627 →
P50867	—	0.979	P50867 →
A0A1W5SR39	—	0.979	A0A1W5SR39 →
P42942	—	0.979	P42942 →
P22414	—	0.979	P22414 →
A1DFA8	—	0.979	A1DFA8 →
P23236	—	0.979	P23236 →
Q03384	—	0.979	Q03384 →
A8E657	—	0.979	A8E657 →
B6H061	—	0.979	B6H061 →
B8M9K0	—	0.979	B8M9K0 →
P00931	—	0.979	P00931 →
A4FUZ6	—	0.979	A4FUZ6 →
B2WMJ3	—	0.979	B2WMJ3 →
A0A6S6QNE4	—	0.979	A0A6S6QNE4 →
P22245	—	0.978	P22245 →
P36858	—	0.978	P36858 →